{"title":"133例癌症IV期临床回顾性分析","authors":"Junjun Guo, W. Gao, Qian Wang, Shenbo Fu, P. Xi","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.02.005","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer. \n \n \nMethods \nClinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model. \n \n \nResults \nThe 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05). \n \n \nConclusion \nRadiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer. \n \n \nKey words: \nEsophageal neoplasm/radiochemotherapy; Esophageal neoplasm/chemotherapy; Prognosis","PeriodicalId":10288,"journal":{"name":"中华放射肿瘤学杂志","volume":"29 1","pages":"102-105"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retrospective clinical analysis of 133 cases of stage IV esophageal cancer\",\"authors\":\"Junjun Guo, W. Gao, Qian Wang, Shenbo Fu, P. Xi\",\"doi\":\"10.3760/CMA.J.ISSN.1004-4221.2020.02.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer. \\n \\n \\nMethods \\nClinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model. \\n \\n \\nResults \\nThe 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05). \\n \\n \\nConclusion \\nRadiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer. \\n \\n \\nKey words: \\nEsophageal neoplasm/radiochemotherapy; Esophageal neoplasm/chemotherapy; Prognosis\",\"PeriodicalId\":10288,\"journal\":{\"name\":\"中华放射肿瘤学杂志\",\"volume\":\"29 1\",\"pages\":\"102-105\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华放射肿瘤学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.02.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.02.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Retrospective clinical analysis of 133 cases of stage IV esophageal cancer
Objective
To investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer.
Methods
Clinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model.
Results
The 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05).
Conclusion
Radiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer.
Key words:
Esophageal neoplasm/radiochemotherapy; Esophageal neoplasm/chemotherapy; Prognosis
期刊介绍:
The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.